Join us on Tuesday, December 15^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck and Taiho Oncology Inc.

Tuesday, December 15, 2020
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

MODULE 1: Hepatocellular Carcinoma (HCC)

• Clinical and biologic factors affecting the selection of first- and later-line treatment for advanced HCC
• Available data with and patient selection for first-line lenvatinib for advanced HCC
• Key efficacy and safety findings from the Phase III IMbrave150 trial leading to the FDA approval of atezolizumab/bevacizumab as first-line therapy for unresectable HCC; optimal integration into routine practice
• Early results with and ongoing studies of other novel strategies combining immune checkpoint inhibition and targeted therapy (eg, lenvatinib/pembrolizumab, lenvatinib/nivolumab, cabozantinib/atezolizumab, cabozantinib/nivolumab/ipilimumab) for newly diagnosed or previously treated advanced HCC
• Selection and sequencing of available targeted agents (eg, regorafenib, cabozantinib, ramucirumab) and immunotherapies (eg, pembrolizumab, nivolumab) for patients who experience disease progression on first-line treatment
• Efficacy and safety findings from the CheckMate 040 trial of nivolumab/ipilimumab for patients with relapsed HCC; recent FDA approval and current clinical role of this regimen
• Early safety and efficacy with and ongoing Phase III evaluation of durvalumab/tremelimumab for HCC

MODULE 2: Cholangiocarcinoma and Pancreatic Cancer

• Spectrum, frequency and clinical implications of targetable molecular alterations among patients with advanced cholangiocarcinoma
• Principle findings contributing to the FDA approval of the selective FGFR inhibitor pemigatinib for patients with pretreated advanced or surgically unresectable cholangiocarcinoma with an FGFR2 translocation; ongoing Phase III evaluation for treatment-naïve disease
• Available evidence with other FGFR-targeted agents (eg, futibatinib, infigratinib, erdafitinib) for advanced or unresectable cholangiocarcinoma
• Outcomes from the Phase III ClarIDHy study evaluating the IDH1 inhibitor ivosidenib for patients with previously treated cholangiocarcinoma with IDH1 mutations; implications for future research and current practice
• Recent clinical trial efforts evaluating the utility of preoperative chemotherapy for patients with resectable or borderline-resectable pancreatic adenocarcinoma (PAD); role of contemporary cytotoxic regimens (modified FOLFIRINOX, nab paclitaxel/gemcitabine) in this setting
• Selection of adjuvant systemic therapy for patients with resected PAD
• Optimal selection and sequencing of available treatments for patients with metastatic PAD; early front-line activity observed with the combination of liposomal irinotecan, 5-FU/leucovorin and oxaliplatin
• FDA approval of maintenance olaparib for metastatic PAD with BRCA mutation and the implications for genetic testing and current nonresearch therapy

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hepatobiliary and pancreatic cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider age, performance status, degree of liver function and other clinical factors in the selection of up-front therapy for patients with newly diagnosed unresectable or metastatic hepatocellular carcinoma (HCC).
• Evaluate Phase III data leading to the recent FDA approval of atezolizumab in combination with bevacizumab as first-line therapy for patients with newly diagnosed unresectable or metastatic HCC, and consider the current role of this novel regimen.
• Recall available clinical trial data with approved and investigational systemic interventions, and where appropriate, apply this information to the clinical care of patients with locally advanced or metastatic HCC who have experienced disease progression on first-line therapy.
• Appraise available clinical trial data documenting the utility of contemporary combination chemotherapy regimens (eg, FOLFIRINOX, nab paclitaxel/gemcitabine) in the neoadjuvant and adjuvant settings, and determine what role, if any, these strategies should play in the current care of patients diagnosed with resectable pancreatic adenocarcinoma (PAD).
• Consider age, performance status, prior therapeutic exposure and other clinical and logistical factors in the selection and sequencing of systemic therapy for patients with locally advanced or metastatic PAD.
• Acknowledge available Phase III data leading to the FDA approval of maintenance olaparib after first-line platinum-based chemotherapy for patients with newly diagnosed PAD and a germline BRCA mutation, and consider the diagnostic and therapeutic implications of these findings for clinical practice.
• Recognize the molecular heterogeneity of cholangiocarcinomas, and apply available clinical research findings in the formulation of evidence-based therapeutic approaches for patients with unresectable or metastatic disease.
• Review the recent FDA approval of pemigatinib for patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, and consider how this agent can be appropriately and safely integrated into clinical management algorithms.
• Recall the biologic rationale for and available and emerging data with other investigational agents currently in clinical testing for HCC, PAD and cholangiocarcinoma, and where applicable, refer eligible patients for trial participation.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of each CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr Bekaii-Saab — Advisory Committee: Immuneering Corporation, Imugene, Sun BioPharma Inc; Consulting Agreements: Array BioPharma Inc, a subsidiary of Pfizer Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Eisai Inc, Exact Sciences, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Natera Inc, Seagen Inc, Sobi, Treos Bio; Contracted Research: AbGenomics, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merus BV, Mirati Therapeutics, Novartis, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Lilly, Merck, Pancreatic Cancer Action Network. Dr Goyal — Advisory Committee: Agios Pharmaceuticals Inc, Alentis Therapeutics AG, Debiopharm Group, H3 Biomedicine, Incyte Corporation, QED Therapeutics, Sirtex Medical Ltd, Taiho Oncology Inc; Consulting Agreements: Agios Pharmaceuticals Inc, Alentis Therapeutics AG, Incyte Corporation, QED Therapeutics, Sirtex Medical Ltd, Taiho Oncology Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Eisai Inc, Exelixis Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck and Taiho Oncology Inc.